**Core Concept**
Palivizumab is a monoclonal antibody that targets the RSV (Respiratory Syncytial Virus) F-protein, preventing its attachment to host cells and subsequent viral replication. It is used in high-risk populations to prevent severe lower respiratory tract infections caused by RSV.

**Why the Correct Answer is Right**
Palivizumab works by binding to the RSV F-protein, thereby preventing the virus from entering host cells. This is particularly effective in premature infants and those with underlying heart disease or lung disease, who are at increased risk of severe RSV infection. The mechanism of action is through the inhibition of RSV F-protein mediated fusion with host cells.

**Why Each Wrong Option is Incorrect**
**Option A:** While palivizumab is used in neonatal care, it is not primarily for preventing Group B strep (GBS) infections, which are typically managed with antibiotics.
**Option B:** Palivizumab is not used for the prophylaxis of pertussis, which is managed with vaccines (DTaP) and antibiotics in some cases.
**Option C:** Palivizumab is not used for the prophylaxis of influenza, which is managed with vaccines (trivalent or quadrivalent) and antiviral medications like oseltamivir.

**Clinical Pearl / High-Yield Fact**
Palivizumab is specifically indicated for the prophylaxis of severe lower respiratory tract infections caused by RSV in high-risk infants, including those born prematurely (less than 29 weeks of gestation) or with underlying heart disease.

**Correct Answer: C. RSV (Respiratory Syncytial Virus)**